Krystal Biotech (KRYS) Cash from Financing Activities (2016 - 2026)

Krystal Biotech has disclosed Cash from Financing Activities across 11 years of filings, most recently posting -$10.5 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$10.5 million, up 16.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.7 million (up 170.16% YoY), and the FY2025 annual result was $8.7 million, down 67.78% from the prior year.
• Cash from Financing Activities came in at -$10.5 million for Q1 2026 at Krystal Biotech, down from $15.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $185.3 million in Q2 2023 to a low of -$12.5 million in Q1 2025.
• The 5-year median for Cash from Financing Activities is $3.1 million (2022), against an average of $15.5 million.
• Across the five-year window, Cash from Financing Activities jumped 15527.14% in 2022 and slumped 217.79% in 2025, its largest moves.
• Krystal Biotech's Cash from Financing Activities stood at $3.1 million in 2022, then retreated by 14.66% to $2.6 million in 2023, then retreated by 7.29% to $2.4 million in 2024, then surged by 545.22% to $15.7 million in 2025, then sank by 166.76% to -$10.5 million in 2026.
• The last three Cash from Financing Activities figures came in at -$10.5 million (Q1 2026), $15.7 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.